Skip to content
MS
rate-limiting unreviewed

Galactose-1-phosphate uridylyltransferase (GALT)

1 reactions · 1 pathways

Clinical / pharmacological. Classic galactosaemia: cataracts, jaundice, E. coli sepsis, intellectual disability

What it does, reaction by reaction

1 reactions

Galactose Metabolism Carbohydrate Metabolism · Cytosol

step 4 Reversible

Galactose-1-phosphate + UDP-glucose → glucose-1-phosphate + UDP-galactose

Converts Galactose-1-phosphate UDP-glucose into Glucose-1-phosphate UDP-galactose

› Notes

Galactose-1-phosphate uridylyltransferase (GALT) exchanges uridyl groups. This central Leloir reaction requires the activated-sugar substrate UDP-glucose; it is reversible, but physiologic flux is directed toward glucose-1-phosphate formation. It is the critical/committed processing step for galactose-1-phosphate.

Showing all 1 reactions.

What accelerates and inhibits it

Regulation is pathway-specific, so each context is listed separately

1 entries

Galactose Metabolism

Listed there as: Galactose-1-phosphate uridylyltransferase

Accelerated by

Galactose-1-phosphate and UDP-glucose availability

Inhibited by

Product accumulation; inherited loss causes substrate trapping

Hormonal control

No major acute hormonal control

Recent literature

Europe PMC · fetched just now · sorted by publication date

  1. 1
    Bispecific antibodies that engage pIgR enrich in mucosa in cynomolgus monkeys.

    Marks K, Shah N, Pham L, Chen J, White I, Burke K, Garrett P, Marella M, Shastri PN, Geist B, Chowdhury P, Ca… · 2026-10-03

    open access unreviewed
  2. 2
    Microplastics and IgA nephropathy: a novel environmental hypothesis of immune dysregulation.

    Shah J, Wells-Gatnik W, Palmer BF, Clegg DJ. · 2026-09-30

    open access unreviewed
  3. 3
    Gut-immune-PVAT axis is involved in ethanol-induced abdominal aortic dysfunction via IL-17RA, TLR4, and FPR1 signaling.

    Brigagão Pacheco da Silva C, Fernandes Rodrigues V, Carlos D, Jordani MC, Naira Zambelli Ramalho L, de Olivei… · 2026-09-21

    open access unreviewed
  4. 4
    The cervicovaginal gut microbiota axis as a key determinant of systemic physiology.

    Rosenn EH, Zuniga M, Lipshitz M, Fox E, Engel M, Pasinetti GM. · 2026-09-21

    open access unreviewed
  5. 5
    Targeting the gut-bone axis in osteoporosis: probiotic interventions and other microbiota-based therapeutic strategies.

    Zhao K, Zhang Z, Tang Z, Man X, Liu J, Feng R, Li K, Jiang Y, Li T. · 2026-09-17

    open access unreviewed
  6. 6
    Towards optimizing the host response to biotics: a report of an International Scientific Association for Probiotics and Prebiotics working group.

    Preidis GA, Bercik P, Marette A, O'Mahony L, Sperandio V, Quigley EM. · 2026-09-08

    open access unreviewed
  7. 7
    Unraveling the drug resistance web in IBD: The gut microbiota-immunity-epigenetics axis.

    Li Q, Cheng M, Wang X, Li W, Zhang F. · 2026-09-01

    open access unreviewed
  8. 8
    Jejunal mucosal immune response in goats ten months after <i>Mycobacterium avium</i> subsp. <i>paratuberculosis</i> challenge is primarily determined by lesion severity rather than vaccination route.

    Criado M, Silva M, Mendívil P, Zapico D, Pérez-Rojo V, Benavides J, Espinosa J, Elguezabal N, Gutiérrez-Expós… · 2026-07-23

    open access unreviewed
  9. 9
    Modulation of the response to immunotherapy in triple-negative breast cancer: the role of the microbiota and microbial metabolites in the tumor microenvironment.

    Serrano-García L, Martínez-Salvador E, Belda-Marco A, Herrero-Oliva C, Cortés J, Llombart-Cussac A, Fernández… · 2026-07-08

    open access unreviewed
  10. 10
    Bridging environmental pollution and immune dysregulation: How microplastics disrupt gut homeostasis to promote allergic diseases.

    Zhang X, Liu K, Zhang Z, Huang X, Liu M, Bai D, Yang R, Yang C. · 2026-06-30

    open access unreviewed

External claims. These come from an index outside this database and are not checked against it. Treat them as leads.